about
Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxationSmoking as a risk factor for erectile dysfunction: data from the Andrology Prevention Weeks 2001-2002 a study of the Italian Society of Andrology (s.I.a.).Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: the PAUSE study.Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients.Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndromeEndogenous urotensin II selectively modulates erectile function through eNOSA systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.Premature ejaculation results in female sexual distress: standardization and validation of a new diagnostic tool for sexual distress.Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function.Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study.Pharmacology of erectile dysfunction in man.The detrusor muscle: an innocent victim of bladder outlet obstruction.Ejaculatory disorders: pathophysiology and management.Androgens and morphologic remodeling at penile and cardiovascular levels: a common piece in complicated puzzles?Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.Thromboprophylaxis in radical retropubic prostatectomy: efficacy and patient compliance of a dual modality.Trauma, gender reassignment, and penile augmentation.A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.Chlamydia trachomatis infection is related to premature ejaculation in chronic prostatitis patients: results from a cross-sectional study.Hydrogen sulfide and erectile function: a novel therapeutic target.Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature.The impact of non-urologic drugs on sexual function in men.Latest pharmacotherapy options for benign prostatic hyperplasia.Clinical aspects of antimicrobial prophylaxis for invasive urological procedures.The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy.Peyronie's disease and autoimmunity—a real-life clinical study and comprehensive review.Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship.In vitro and in vivo TNFalpha synthesis modulation by methylguanidine, an uremic catabolyte.Differential in vivo urodynamic measurement in a single thin catheter based on two optical fiber pressure sensors.A snapshot of nephron-sparing surgery in Italy: a prospective, multicenter report on clinical and perioperative outcomes (the RECORd 1 project).Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?A prospective, multicenter evaluation of predictive factors for positive surgical margins after nephron-sparing surgery for renal cell carcinoma: the RECORd1 Italian Project.Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs.A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.An ex vivo standardized assay to measure human platelet cGMP.Sildenafil effect on the human bladder involves the L-cysteine/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors.
P50
Q24656291-DE8B000F-72A3-4B4A-BFEA-EB80ACAEF70AQ31009150-3CBEABF7-9505-4AB7-B6A8-7189F37B1BF8Q33163214-6415A922-083C-41F4-88C8-859F0A9D3540Q33382613-0DA73343-5C39-44AC-97A5-FAADCD68F1A0Q33582528-314F79A8-1F60-4BA9-94C0-08DEAF9AEA70Q34119587-4BDB4904-F43C-4C03-8BF7-60D6152578BCQ34154714-A1F212DE-5B51-45E0-9166-92F2E53AFFEFQ34190455-319C7A10-9EB1-4D5A-AF81-54B72BA03807Q34311029-BB19E17F-7073-4928-A873-D89FD65A0B34Q34983511-848EFB2C-F47E-440A-A080-2BBA93E08051Q35990762-D2108A61-C58F-4216-8F21-4A74B8BA8BCFQ36380335-B47D297F-1832-41D7-A2D3-DE5EC32996F5Q36595583-1AC4E3E9-A7FC-43D0-ABF5-11707CCDB415Q37079700-CFC15785-364E-41D2-9FE6-59F3AE5BC87DQ37369488-68609D20-FBC1-45C0-9130-B4747F48F25BQ37372803-063DA812-11B9-48C5-B62E-676AA865426EQ37467019-5C69FDF5-569F-4ECA-B6B1-D0CBE4B9F3F5Q37730215-42EEB7D7-4585-4F47-B3E7-1C1350F71C12Q37765650-BB487F22-ED43-4852-833D-60717FBACFFDQ37795307-92339E08-BC4D-417D-BC7E-433DFBB126C3Q37843481-27DC5E7F-313B-42C5-B28F-5025E1829E8EQ37862060-084982EC-6AB0-4048-80C8-F250734BF5E4Q37897389-BD379B56-94BF-42E7-A6C5-A92ED2885386Q38161511-8BEE2A82-F05B-4D7D-986E-477F64BA2516Q38202475-7BFDFD20-9DBB-4C25-95D7-BA75BC9860D5Q38244053-B7F7F1C5-DC6D-4EAA-A608-4B609798E634Q38253256-BD69087B-07FC-485C-9CCA-1AAC5A989434Q38259866-5ABDD9E8-924F-4289-8F5F-F9019FA2884FQ38335739-934C55CF-2ADA-4B1D-AC86-0AE768C5AED0Q38532568-D201F306-136B-40A3-8BD5-C9B14DBC8AE3Q40910767-3A550BDD-FAE3-4385-B292-5BBCE9E78EBCQ40926081-565789FA-A2E6-4A65-A44B-7736B7DA1BC3Q41256343-F3BA5D94-D76A-4A7A-B216-8EEC1F1677C0Q41590170-84657566-7B65-4E58-B268-E62B278C4A94Q41709993-6D487D2A-18A2-405B-A461-B9B89FAB8A22Q41755718-D8C6AAF7-B49B-4654-824F-451395E074ACQ41758679-20360974-8CC1-484B-A3BC-5F4B94407930Q42139903-44AC0285-5C8D-4AB9-AF30-A97F7AEE0195Q42492332-7D907960-B720-4C73-B177-7E4F2E5F4865Q42510309-B4C145BE-E7A4-4C2E-85F5-2A8C7AD4AAF2
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Vincenzo Mirone
@ast
Vincenzo Mirone
@en
Vincenzo Mirone
@es
Vincenzo Mirone
@nl
type
label
Vincenzo Mirone
@ast
Vincenzo Mirone
@en
Vincenzo Mirone
@es
Vincenzo Mirone
@nl
prefLabel
Vincenzo Mirone
@ast
Vincenzo Mirone
@en
Vincenzo Mirone
@es
Vincenzo Mirone
@nl
P106
P1153
7005314294
P21
P214
7155564065913002574
P31
P496
0000-0002-7639-2560
P735
P7859
viaf-7155564065913002574